178 related articles for article (PubMed ID: 37154968)
1. Diffuse Sclerosing Papillary Thyroid Carcinoma: Clinicopathological Characteristics and Prognostic Implications Compared with Classic and Tall Cell Papillary Thyroid Cancer.
Scholfield DW; Fitzgerald CW; Alzumaili B; Eagan A; Xu B; Martinez G; Tuttle RM; Shaha AR; Shah JP; Wong RJ; Patel SG; Ghossein RA; Ganly I
Ann Surg Oncol; 2023 Aug; 30(8):4761-4770. PubMed ID: 37154968
[TBL] [Abstract][Full Text] [Related]
2. Impact of tall cell variant histology on predicting relapse and changing the management of papillary thyroid carcinoma patients.
Gunalp B; Okuyucu K; Ince S; Ayan A; Alagoz E
Hell J Nucl Med; 2017; 20(2):122-127. PubMed ID: 28697188
[TBL] [Abstract][Full Text] [Related]
3. Papillary thyroid carcinoma tall cell subtype (PTC-TC) and high-grade differentiated thyroid carcinoma tall cell phenotype (HGDTC-TC) have different clinical behaviour: a retrospective study of 1456 patients.
Ghossein R; Katabi N; Dogan S; Shaha AR; Tuttle RM; Fagin JA; Ganly I; Xu B
Histopathology; 2024 Jun; 84(7):1130-1138. PubMed ID: 38528726
[TBL] [Abstract][Full Text] [Related]
4. Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.
Shi X; Liu R; Basolo F; Giannini R; Shen X; Teng D; Guan H; Shan Z; Teng W; Musholt TJ; Al-Kuraya K; Fugazzola L; Colombo C; Kebebew E; Jarzab B; Czarniecka A; Bendlova B; Sykorova V; Sobrinho-Simões M; Soares P; Shong YK; Kim TY; Cheng S; Asa SL; Viola D; Elisei R; Yip L; Mian C; Vianello F; Wang Y; Zhao S; Oler G; Cerutti JM; Puxeddu E; Qu S; Wei Q; Xu H; O'Neill CJ; Sywak MS; Clifton-Bligh R; Lam AK; Riesco-Eizaguirre G; Santisteban P; Yu H; Tallini G; Holt EH; Vasko V; Xing M
J Clin Endocrinol Metab; 2016 Jan; 101(1):264-74. PubMed ID: 26529630
[TBL] [Abstract][Full Text] [Related]
5. Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma?
Song E; Jeon MJ; Oh HS; Han M; Lee YM; Kim TY; Chung KW; Kim WB; Shong YK; Song DE; Kim WG
Eur J Endocrinol; 2018 Sep; 179(3):135-142. PubMed ID: 29875289
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of papillary thyroid carcinoma with tall-cell features.
Ganly I; Ibrahimpasic T; Rivera M; Nixon I; Palmer F; Patel SG; Tuttle RM; Shah JP; Ghossein R
Thyroid; 2014 Apr; 24(4):662-70. PubMed ID: 24262069
[TBL] [Abstract][Full Text] [Related]
7. Survival of aggressive variants of papillary thyroid carcinoma in patients under 55 years old: a SEER population-based retrospective analysis.
Feng J; Shen F; Cai W; Gan X; Deng X; Xu B
Endocrine; 2018 Sep; 61(3):499-505. PubMed ID: 29909599
[TBL] [Abstract][Full Text] [Related]
8. A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases.
Regalbuto C; Malandrino P; Tumminia A; Le Moli R; Vigneri R; Pezzino V
Thyroid; 2011 Apr; 21(4):383-9. PubMed ID: 21309722
[TBL] [Abstract][Full Text] [Related]
9. Comparison of histopathological features and prognosis of classical and follicular variant papillary thyroid carcinoma.
Tunca F; Sormaz IC; Iscan Y; Senyurek YG; Terzioglu T
J Endocrinol Invest; 2015 Dec; 38(12):1327-34. PubMed ID: 26280320
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic features and prognostic factors of tall cell variant of papillary thyroid carcinoma: comparison with classic variant of papillary thyroid carcinoma.
Okuyucu K; Alagoz E; Arslan N; Emer O; Ince S; Deveci S; Ayan A; Taslipinar A; Gunalp B; Azal O
Nucl Med Commun; 2015 Oct; 36(10):1021-5. PubMed ID: 26225942
[TBL] [Abstract][Full Text] [Related]
11. Tall cell and diffuse sclerosing variants of papillary thyroid cancer: outcome and predicting value of risk stratification methods.
Russo M; Malandrino P; Moleti M; Vermiglio F; Violi MA; Marturano I; Minaldi E; Vigneri R; Pellegriti G; Regalbuto C
J Endocrinol Invest; 2017 Nov; 40(11):1235-1241. PubMed ID: 28528434
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors Associated With Recurrence and Death in Patients With Tall Cell Papillary Thyroid Cancer: A Single-Institution Cohort Study With Predictive Nomogram.
Wu SS; Joshi N; Sharrett J; Rao S; Shah A; Scharpf J; Burkey B; Lamarre ED; Prendes B; Siperstein A; Shin J; Berber E; Jin J; Krishnamurthi V; Nasr C; Hong L; Buchberger DS; Woody N; Koyfman SA; Geiger JL
JAMA Otolaryngol Head Neck Surg; 2023 Jan; 149(1):79-86. PubMed ID: 36454559
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the clinicopathological features and prognoses of the classical and the tall cell variant of papillary thyroid cancer: a meta-analysis.
Liu Z; Zeng W; Chen T; Guo Y; Zhang C; Liu C; Huang T
Oncotarget; 2017 Jan; 8(4):6222-6232. PubMed ID: 28009980
[TBL] [Abstract][Full Text] [Related]
14. Tall cell variant papillary thyroid carcinoma impacts disease-free survival at the 10 % cut-point on multivariate analysis.
Samankan S; Militello L; Seo G; Everest S; O'Malley Q; Spaulding SL; Xing M; Matloob A; Beute J; Chai R; Doyle S; Urken ML; Brandwein-Weber M
Pathol Res Pract; 2022 Aug; 236():154012. PubMed ID: 35834884
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological Characteristics and Recurrence-Free Survival of Rare Variants of Papillary Thyroid Carcinomas in Korea: A Retrospective Study.
Kim M; Cho SW; Park YJ; Ahn HY; Kim HS; Suh YJ; Choi D; Kim BK; Yang GE; Park IS; Yi KH; Jung CK; Kim BH
Endocrinol Metab (Seoul); 2021 Jun; 36(3):619-627. PubMed ID: 34107674
[TBL] [Abstract][Full Text] [Related]
16. The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases.
Eloy C; Santos J; Soares P; Sobrinho-Simões M
Virchows Arch; 2011 Sep; 459(3):265-76. PubMed ID: 21796448
[TBL] [Abstract][Full Text] [Related]
17. Diffuse intrathyroidal dissemination of papillary thyroid carcinoma with no stromal fibrosis at presentation: A pattern of aggressive differentiated thyroid carcinoma.
Fang H; Si Y; Wang C; Gong Q; Liu C; Wang S
Pathol Res Pract; 2021 Aug; 224():153510. PubMed ID: 34329840
[TBL] [Abstract][Full Text] [Related]
18. Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma Is Associated With Aggressive Histopathological Features and a Poor Outcome: Results of a Large Multicentric Study.
Chereau N; Giudicelli X; Pattou F; Lifante JC; Triponez F; Mirallié E; Goudet P; Brunaud L; Trésallet C; Tissier F; Leenhardt L; du Montcel ST; Menegaux F
J Clin Endocrinol Metab; 2016 Dec; 101(12):4603-4610. PubMed ID: 27626975
[TBL] [Abstract][Full Text] [Related]
19. Investigating the impact of tumor location and size on the risk of recurrence for papillary thyroid carcinoma in the isthmus.
Zhu F; Li F; Xie X; Wu Y; Wang W
Cancer Med; 2023 Jun; 12(12):13290-13299. PubMed ID: 37132252
[TBL] [Abstract][Full Text] [Related]
20. A Comparison of Clinicopathological Characteristics and Short-Term Outcome of Papillary Thyroid Carcinoma with Tall Cell Histology and Classic Papillary Thyroid Carcinoma: A Single-Institution Experience.
Sampathkumar G; Nair V; Menon UV; Smitha NV; Sundaram S; Kumar H; Pavithran PV; Bhavani N; Menon AS; Abraham N; Pullikkal A
Indian J Endocrinol Metab; 2018; 22(3):405-409. PubMed ID: 30090735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
